C2M
PopularA neo-epitope fragment of type II collagen generated by matrix metalloproteinase activity, enabling direct assessment of cartilage degradation and turnover.
Key features and values
- Detects degradation fragments of type II collagen formed by matrix metalloproteinase activity.
- Provides a direct, non-invasive measure of cartilage breakdown in joint and connective tissue disorders.
- Reflects pathological extracellular matrix remodeling processes in degenerative and inflammatory conditions.
- Supports dynamic monitoring of disease activity and cartilage integrity over time.
- Facilitates assessment of therapeutic response in clinical and research settings.
- Enables stratification of patients based on molecular markers of cartilage turnover.
- Informs research on mechanisms of cartilage degeneration and tissue remodeling.
Description
The C2M biomarker assay quantifies neo-epitope fragments of type II collagen produced by matrix metalloproteinase-driven cleavage, serving as a specific indicator of cartilage degradation and extracellular matrix remodeling. This non-invasive assay enables the monitoring of cartilage turnover in degenerative and inflammatory joint diseases, providing insight into disease mechanisms, activity, and response to therapeutic interventions. C2M is instrumental in research and clinical studies focused on understanding and modulating cartilage breakdown and connective tissue remodeling.
Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.
